A PYMNTS Company

Not Another Drug! Antitrust for Drug and Other Innovations

By  |  January 24, 2016

Posted by Social Science Research Network

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Not Another Drug! Antitrust for Drug and Other Innovations

    Richard Gilbert (University of California)

    Abstract:     A number of antitrust cases have challenged firm conduct associated with the introduction of a new product. Several are in the pharmaceutical industry and have earned the moniker of “product hopping.” Other cases involve the design of interfaces that defeat interoperability and the supply of integrated products that curtail demand for one or more of the integrated components. I propose a framework to compare the costs and benefits of single-firm conduct involving innovation and offer two suggestions for “almost safe” harbors. One is a transition to a new product that is accomplished without constraining consumer choices among existing products. The second “almost safe” harbor is for the development of an improved product, interface or design that impacts the supply of complementary products or services, provided that these complements do not offer a pathway for competition that would undermine monopoly power.